Publication date: November 2026 Source: Blood Neoplasia, Volume 3, Issue 4 Author(s): Andrew P. Jallouk, Lorenzo Falchi, Ayushi Chauhan, Geoffrey Shouse, Swetha K. Thiruvengadam, Yazeed Sawalha, Sonia Godbole, Ajay Major, Reid W. Merryman, Shakthi T. Bhaskar, Allison M. Bock, Mehdi Hamadani, Amy Ayers, Omnia Farahat, Narendranath Epperla, Jennifer L. Crombie, Steven Bair, Mathew A. Lunning, Alex F. Herrera, Christopher R. Flowers
Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis. // Blood Neoplasia. – URL: https://www.sciencedirect.com/science/article/pii/S2950328026000919?dgcid=rss_sd_all
Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis. Blood Neoplasia. https://www.sciencedirect.com/science/article/pii/S2950328026000919?dgcid=rss_sd_all
“Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis.” Blood Neoplasia.
@article{article38541,
title = {Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis},
journal = {Blood Neoplasia},
url = {https://www.sciencedirect.com/science/article/pii/S2950328026000919?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment